Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD

8.13  +0.17 (+2.14%)

After market: 8.13 0 (0%)

Fundamental Rating

4

Overall AMRX gets a fundamental rating of 4 out of 10. We evaluated AMRX against 193 industry peers in the Pharmaceuticals industry. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

AMRX had positive earnings in the past year.
The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
In the past 5 years AMRX always reported a positive cash flow from operatings.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

With an excellent Return On Assets value of -0.39%, AMRX belongs to the best of the industry, outperforming 80.31% of the companies in the same industry.
AMRX has a better Return On Invested Capital (11.15%) than 89.12% of its industry peers.
AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is significantly below the industry average of 14.96%.
The last Return On Invested Capital (11.15%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.39%
ROE N/A
ROIC 11.15%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

AMRX has a better Operating Margin (12.87%) than 83.94% of its industry peers.
In the last couple of years the Operating Margin of AMRX has grown nicely.
AMRX has a Gross Margin of 36.69%. This is comparable to the rest of the industry: AMRX outperforms 59.07% of its industry peers.
In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 12.87%
PM (TTM) N/A
GM 36.69%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
AMRX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMRX has more shares outstanding
The debt/assets ratio for AMRX has been reduced compared to a year ago.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.54, we must say that AMRX is in the distress zone and has some risk of bankruptcy.
AMRX has a better Altman-Z score (1.54) than 62.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.54
ROIC/WACC1.04
WACC10.68%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 1.40 indicates that AMRX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.40, AMRX is not doing good in the industry: 70.47% of the companies in the same industry are doing better.
A Quick Ratio of 0.84 indicates that AMRX may have some problems paying its short term obligations.
With a Quick ratio value of 0.84, AMRX is not doing good in the industry: 81.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 0.84
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.46% over the past year.
AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
Looking at the last year, AMRX shows a quite strong growth in Revenue. The Revenue has grown by 16.73% in the last year.
The Revenue has been growing by 11.43% on average over the past years. This is quite good.
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%

3.2 Future

Based on estimates for the next years, AMRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.95% on average per year.
Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y23.98%
EPS Next 2Y20.63%
EPS Next 3Y21.77%
EPS Next 5Y11.95%
Revenue Next Year8.67%
Revenue Next 2Y8.03%
Revenue Next 3Y8.15%
Revenue Next 5Y0.6%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.99 indicates a reasonable valuation of AMRX.
Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 89.64% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of AMRX to the average of the S&P500 Index (27.03), we can say AMRX is valued rather cheaply.
A Price/Forward Earnings ratio of 9.63 indicates a reasonable valuation of AMRX.
AMRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 83.42% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.28. AMRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.99
Fwd PE 9.63
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

AMRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMRX is cheaper than 89.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.89
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AMRX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 21.77% in the coming years.
PEG (NY)0.46
PEG (5Y)1.03
EPS Next 2Y20.63%
EPS Next 3Y21.77%

More info and screens

0

5. Dividend

5.1 Amount

AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (8/5/2025, 8:00:00 PM)

After market: 8.13 0 (0%)

8.13

+0.17 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-07 2025-11-07/bmo
Inst Owners40.32%
Inst Owner Change-1.22%
Ins Owners46.63%
Ins Owner Change2.56%
Market Cap2.55B
Analysts82
Price Target11.99 (47.48%)
Short Float %3.49%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.76%
Min EPS beat(2)-22.85%
Max EPS beat(2)40.37%
EPS beat(4)3
Avg EPS beat(4)11.74%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)33.87%
EPS beat(12)9
Avg EPS beat(12)22.89%
EPS beat(16)11
Avg EPS beat(16)18.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-4.71%
Max Revenue beat(2)1.22%
Revenue beat(4)2
Avg Revenue beat(4)-0.03%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)4.54%
Revenue beat(8)5
Avg Revenue beat(8)0.71%
Revenue beat(12)8
Avg Revenue beat(12)0.66%
Revenue beat(16)9
Avg Revenue beat(16)-0.12%
PT rev (1m)0.71%
PT rev (3m)2.17%
EPS NQ rev (1m)2.94%
EPS NQ rev (3m)-2.78%
EPS NY rev (1m)-0.24%
EPS NY rev (3m)3.68%
Revenue NQ rev (1m)-1.17%
Revenue NQ rev (3m)-2.64%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE 10.99
Fwd PE 9.63
P/S 0.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 7.89
EPS(TTM)0.74
EY9.1%
EPS(NY)0.84
Fwd EY10.38%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS9.03
BVpS-0.42
TBVpS-4.53
PEG (NY)0.46
PEG (5Y)1.03
Profitability
Industry RankSector Rank
ROA -0.39%
ROE N/A
ROCE 15.91%
ROIC 11.15%
ROICexc 11.42%
ROICexgc 23.32%
OM 12.87%
PM (TTM) N/A
GM 36.69%
FCFM N/A
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexcg growth 3Y25.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-ScoreN/A
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 4.16
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 0.84
Altman-Z 1.54
F-ScoreN/A
WACC10.68%
ROIC/WACC1.04
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
EPS Next Y23.98%
EPS Next 2Y20.63%
EPS Next 3Y21.77%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%
Revenue Next Year8.67%
Revenue Next 2Y8.03%
Revenue Next 3Y8.15%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year11.33%
EBIT Next 3Y10.45%
EBIT Next 5Y3.87%
FCF growth 1Y-20.36%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y-14.61%
OCF growth 3Y6.86%
OCF growth 5Y180.48%